

Span Divergent Ltd. (Formerly Span Diagnostics Ltd.)

9th Floor, Rajhans Bonista, Behind Ram Chowk, Ghod Dod Road,

Surat - 395 007, Gujarat, India Phone: +91 261 266 32 32 E-Mail: contact@span.in

Date: August 13, 2025

To, Listing Compliance Department Bombay Stock Exchange Limited Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400 001

Scrip Code: 524727

Subject: Submission of Un-audited Financial Results (Consolidated & Standalone) of the Company for the First Quarter and Three Months ended June 30, 2025

Listing Regulation: Regulation 33 & all other applicable Regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time to time.

Dear Sir/Madam,

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to forward herewith the Unaudited Financial Results of the Company comprising both Standalone Financial Results and Consolidated Financial Results for the quarter ended June 30, 2025 along with Limited Review Reports issued by the Statutory Auditors on the said financial results.

The said Financial Results comprising both Standalone Financial Results and Consolidated Financial Results for the quarter ended June 30, 2025 have been approved by Board of Directors at their meeting held on Wednesday, August 13, 2025.

The Board meeting commenced at 11:15 (IST) and concluded at 14:00 (IST).

You are therefore requested to take the above information on records.

Thanking You.

Yours faithfully,

For Span Divergent Limited

Viral Desai Managing Director DIN 00029219

Encl: As above

CIN: L74999GJ1980PLC003710

www.span.in

Span Divergent Limited

(Formerly known as Span Diagnostics Limited)

Regd.Office: 9th Floor, 902-904, Rajhans Bonista, Behind Ram Chowk Temple, Ghod Dod Road, Surat-395007

CIN:L74999GJ1980PLC003710 Website: www.span.in

Statement of unaudited Financial Result for the quarter ended June 30, 2025.

(Rs in Lakhs)

Sr. No.	Particulars				
		Three Months			
		Quarter ended 30 June 2025 Unaudited	Quarter ended 31 Mar 2025 Audited	Quarter ended 30 June 2024 Unaudited	Year ended 31 Mar 2025 Audited
1	Income from operations				
	Other Operating Income	38.45	32.06	51.28	160.99
	Other income	26.48	36.30	22.26	115.20
	Total income	64.93	68.36	73.55	276.19
2	Expenses				
	Purchases of stock-in-trade		-		
	Changes in inventories of work-in-progress, stock-in-trade and finished goods				
	Employee benefit expense	26.92	35.39	26.41	119.54
	Finance costs	20.72	33.37	20.41	117.54
	Depreciation and amortisation expense	6.28	6.30	6.31	25.16
	Donation Donation	0.20	0.50	0.31	25.10
	Other expenses	7.99	12.49	9.38	39.10
	Total expenses	41.19	54.18	42.10	183.80
	Profit / (Loss) before exceptional items and tax (1-2)	23.74	14.18	31.45	92.39
3	Trone / (2005) before exceptional reems and tax (+ 2)	25			, 2.0,
4	Exceptional items (Refer Note 5)	19.00		2.00	5.66
5	Profit/(Loss) before tax (3-4)	42.74	14.18	33.45	98.05
6	Tax expense:				
	- Current tax				
	- Deferred tax	1.07	0.98	10.36	14.09
7	Profit/(Loss) for the period after tax (5-6)	41.67	13.20	23.08	83.96
8	Other comprehensive income				
	Item that will not be reclassified to Profit or Loss (Consisting				
	of re-measurement of net defined benefit liabilities)	(0.18)	0.47	(0.40)	(0.73)
	Income tax relating to items that will not be reclassified to				
	Profit or Loss	0.05	(0.13)	0.11	0.20
9	Total comprehensive income for the year (7+8)	41.54	13.54	22.79	83.43
10	Paid-up equity share capital (Face value of Rs. 10/- each)	546.17	546.17	546.17	546.17
11	Other Equity			•	2,929.25
	Earnings per equity share for profit from operation attributable to owners of the entity:				
12	Basic earnings per share	0.76	0.24	0.42	1.54
13	Diluted earnings per share	0.76	0.24	0.42	1.54





Note: -

Place: Surat

Date: August 13, 2025

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 13, 2025
- Other Operating Income comprises of Interest on fluctuating capital provided by the Company to its LLP subsidiaries and management fees income which is based on the revenue earned by subsidiaries during the quarter.
- 3 In case of subsidiary:
 - (a) Aranya Agri Biotech LLP had accumulated losses of Rs. 15.12 Crores till March 31 2025 and gain of Rs. 0.19 crore in the current year, up to June 30, 2025. In light of the accumulated losses and business scenario going forward, Board has approved the plan for discontinuation of operations of the LLP and the Assets of the LLP have been classified as Asset held for sale w.e.f September 30, 2023.
 - (b) Biospan Scientific LLP had accumulated losses of Rs.1.57 Crores as at 31st March 2019, resulting in substantial erosion of the net worth of the LLP. Hence the Management had decided to impair the investment and Rs. 1.83 Crores were provided in the books of the Company and was treated as an exceptional item during the year 2018-19. Notwithstanding the above, the financial results of the LLP has been prepared on going concern basis as Management is exploring the possibilities to revive the LLP on its own or by entering in to business tieups and it endeavours to be able to establish profitable operation.
 - (c) Biospan Contamination Control Solutions Pvt. Ltd had accumulated losses of Rs. 6.54 Crores till June 30, 2025. As on March 31, 2025 that the subsidiary Company's total liabilities exceeded its total assets by Rs. 6.35 Crores. Notwithstanding the above, the financial results of the subsidiary Company has been prepared on going concern basis as Management believes that the company would be able to establish profitable operation and the losses incurred is attributable to factors of temporary nature. Further, Management is confident that with appropriate product introductions, the Company will achieve adequate revenue and negative net worth would turn positive in short term horizon.
- 4 Previous periods figures have been regrouped and rearranged wherever necessary.
- The financial results of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 read with the relevant rules of the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016.
- The above financial results are also available on the Company's website www.span.in and BSE Limited's website www.bseindia.com.

For Span Divergent Limited

Viral Des

Viral Desai Managing Director DIN: 00029219

SURAT SURAT



Span Divergent Ltd.

(Formerly Span Diagnostics Ltd.)
9th Floor, Rajhans Bonista,
Behind Ram Chowk, Ghod Dod Road,
Surat - 395 007, Gujarat, India

Phone: +91 261 266 32 32 E-Mail: contact@span.in

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC – NOT APPLICABLE

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES

Sr. No.	Particulars	in INR crore			
1.	Loans / revolving facilities like cash credit from banks / financial institutions				
Α	Total amount outstanding as on June 30, 2025	Nil			
В	Of the total amount outstanding, amount of default as on June 30, 2025	Nil			
2.	Unlisted debt securities i.e. NCDs and NCRPS				
Α	Total amount outstanding as on June 30, 2025	Not Applicable			
В	Of the total amount outstanding, amount of default as on June 30, 2025	Not Applicable			
3.	Total financial indebtedness of the listed entity including short- term and long-term debt as on June 30, 2025	1.92*			

^{*}Represents amounts outstanding unsecured loan from Directors

- D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) NOT APPLICABLE
- E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONGWITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) NOT APPLICABLE



VD32

Span Divergent Limited

(Formerly known as Span Diagnostics Limited)

Regd.Office: 9th Floor, 902-904, Rajhans Bonista, Behind Ram Chowk Temple, Ghod Dod Road, Surat-395007

CIN:L74999GJ1980PLC003710 Website: www.span.in

Statement of Consolidated unaudited Results for the Quarter ended June 30, 2025.

(Rs. In Lakhs)

Sr.	Particulars	Consolidated Results				
No.		Three Months				
		Quarter ended 30 June 2025	Quarter ended 31 March 2025	Quarter ended 30 June 2024	Year ended 31 March 2025	
		Unaudited	Audited	Unaudited	Audited	
1	Income from operations					
	Sale of Traded Products/Services	96.23	49.58	352.25	855.01	
	Other Operating Income	10.80	5.25	18.75		
	Other income	72.18	33.58	17.52	118.84	
	Income from Discontinued operations	170.01	20.44	200 50	1.011.05	
	Total income	179.21	88.41	388.52	1,014.85	
2	Expenses					
	Cost of materials consumed Purchases of stock-in-trade	423.99	30.85	92.58	279.65	
		(354.23)	8.66	46.19	16.29	
	Changes in inventories of work-in-progress, stock-in-trade and finished goods	(334.23)	8.00	40.17	10.29	
	Employee benefit expense	51.16	59.93	52.51	230.51	
	Finance costs	11.92	14.63	16.22	60.39	
	Depreciation and amortisation expense	27.23	23.77	28.18	108.80	
	Other expenses	52.60	49.27	152.65	433.21	
	Total expenses	212.67	187.11	388.33	1,128.85	
3	Profit / (Loss) before tax and Exceptional items (1-2)	(33.46)	(98.70)	0.19	(114.00)	
4	Exceptional items	19.00		2.00	5.66	
5	Profit/(Loss) before tax (3-4)	(14.46)	(98.70)	2.19	(108.34)	
6	Tax expense:					
	- Current tax					
	- Deferred tax	2.55	3.69	10.72	19.03	
7	Profit/(Loss) for the period after tax (5-6)	(17.01)	(102.39)	(8.53)	(127.37)	
	Profit for the year attributable to:					
	(a) Owners of the Company	(9.83)	(88.60)	(0.55)	(91.73)	
	(b) Non Controlling Interest	(7.18)	(13.79)	(7.98)	(35.64)	
		(17.01)	(102.39)	(8.53)	(127.38)	
8	Other comprehensive income Item that will not be reclassified to Profit or Loss (Consisting of re-measurement of net defined benefit liabilities)	(0.005)	(1.20)	0.39	(0.02)	
	Income tax relating to items that will not be reclassified to Profit or Loss	0.005	0.46	(0.15)	0.02	
	Other comprehensive income	(0.01)	(0.74)	0.24	0.01	
	Other comprehensive income attributable to:					
	(a) Owners of the Company	0.04	(0.69)	0.29	0.22	
	(b) Non Controlling Interest	(0.05)	(0.04)	(0.06)		
		(0.01)	(0.74)	0.23	(0.00)	
•	T-t-1 (7.8)	(47.02)	(402.42)	(0.20)	(427.27)	
9	Total comprehensive income for the year (7+8) Total comprehensive income attributable to:	(17.02)	(103.13)	(8.29)	(127.37)	
	(a) Owners of the Company	(9.89)	(89.38)	(0.37)	(91.95)	
	(b) Non Controlling Interest	(7.12)	(13.75)	(7.92)		
	(b) Non-controlling interest	(17.02)	(103.13)	(8.29)		
10	Paid-up equity share capital (Face value of Rs. 10/- each)	546.17	546.17	546.17	546.17	
11	Other Equity				(826.86)	
	Earnings per equity share for profit from operation				(020.00)	
	Davis and the same of the same	(0.31)	(1.87)	(0.16)	(2.33)	
12	Ibasic earnings per snare	10.311				



Note: -

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 13, 2025.
- The financial results of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 read with the relevant rules of the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards)(Amendment) Rules, 2016.
- 3 In case of subsidiary:

Place : Surat

Date: August 13, 2025

- (a) Aranya Agri Biotech LLP had accumulated losses of Rs. 15.12 Crores till March 31 2025 and gain of Rs. 0.19 crore in the current year, up to June 30, 2025. In light of the accumulated losses and business scenario going forward, Board has approved the plan for discontinuation of operations of the LLP and the Assets of the LLP have been classified as Asset held for sale w.e.f September 30, 2023.
- (b) Biospan Scientific LLP had accumulated losses of Rs.1.57 Crores as at 31st March 2019, resulting in substantial erosion of the net worth of the LLP. Hence the Management had decided to impair the investment and Rs. 1.83 Crores were provided in the books of the Company and was treated as an exceptional item during the year 2018-19. Notwithstanding the above, the financial results of the LLP has been prepared on going concern basis as Management is exploring the possibilities to revive the LLP on its own or by entering in to business tie-ups and it endeavours to be able to establish profitable operation.
- (c) Biospan Contamination Control Solutions Pvt. Ltd had accumulated losses of Rs.6.54 Crores till June 30, 2025. As on March 31, 2025 that the subsidiary Company's total liabilities exceeded its total assets by Rs. 6.35 Crores. Notwithstanding the above, the financial results of the subsidiary Company has been prepared on going concern basis as Management believes that the company would be able to establish profitable operation and the losses incurred is attributable to factors of temporary nature. Further, Management is confident that with appropriate product introductions, the Company will achieve adequate revenue and negative net worth would turn positive in short term horizon.
- 4 The corresponding figures for the quarter ended 30th June, 2025 and 31st March, 2025 were approved by the Board of Directors, but have not been subject to review by the statutory auditors.
- 5 Previous quarters and periods figures have been regrouped and rearranged wherever necessary.

For, Span Divergent Limited

Viral Desai Managing Director

DIN: 00029219



6. Consolidated Segment Revenue, Results Assets and Liability as at June 30, 2025.					(Rs. In Lakhs)
Sr. No.	Particulars		Three Months		V
		Quarter ended 30 June 2025	Quarter ended 31 Mar 2025	Quarter ended 30 June 2024	Year ended 31 March 2025
		Unudited	Audited	Unudited	Audited
1	Segment Revenue				
	- Cashew processing	15.27	1.59	276.77	585.62
	- Tissu Culture			72 3 4	
	- Trading	111.34	50.56	77.21	294.59
	Gross Revenue from Operations from Segments	126.61	52.14	353.98	880.22
	Less : Inter Segment Revenue				
	Net Revenue from Operations from Segments	126.61	52.14	353.98	880.22
2	Segment Results				
	Profit / (Loss) before Interest and tax				
	- Cashew processing	(65.91)	(89.37)	(23.22)	(160.55)
	- Tissu Culture	-		(1.28)	
	- Trading	(11.25)	(25.80)	(6.72)	(47.28)
	- Unallocable income over expenses like				
	(Including HO)	62.70	16.47	33.39	99.49
	Total Profit / (Loss) before Tax	(14.46)	(98.70)	2.17	(108.34)
3	Segment Assets				
	- Cashew processing	1,215.56	880.18	1,015.21	880.18
	- Tissu Culture	70.59	90.44	47.93	90.44
	- Trading	376.41	328.05	214.08	328.05
	- Unallocable	4,086.19	1,021.56	5,617.43	1,021.56
	Total Assets	5,748.75	2,320.22	6,894.65	2,320.22
4	Segment Liability				
	- Cashew processing	621.42	294.90	743.75	294.90
	- Tissu Culture	9.75	29.56	132.21	29.56
	- Trading	873.99	814.39	676.28	814.39
	- Unallocable	569.07	2,065.50	2,182.95	2,065.50
	Total Liability	2,074.23	3,204.36	3,735.19	3,204.36

For Span Divergent Limited

Place : Surat

Date : August 13, 2025

Viral Desai Managing Director DIN: 00029219



: 247424

Fax: 2464054

1 / 573, 1st FLOOR, GAJANAND COMPLEX, POR MOHALLOW, NEAR ANAND HOSPITAL, NANPURA, SURAT - 395 001.

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report
To the Board of Directors of
Span Divergent Ltd.

- 1. We have reviewed the accompanying statement of unaudited standalone financial results of Span Divergent Limited (the "Company") for the quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the companies Act,2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Y. B. Desai and Associates
Chartered Accountants
Firm Registration No. 102368W

Mayank Y. Desai

Partner

Membership No.: - 108310

UDIN: 25108310 BMISNE 8586

Date: - 13th August, 2025

Place :- Surat

: 247424 : 246585 : 246585

Fax: 2464054

1 / 573, 1st FLOOR, GAJANAND COMPLEX, POR MOHALLOW, NEAR ANAND HOSPITAL, NANPURA, SURAT - 395 001.

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report
To the Board of Directors of
Span Divergent Ltd.

- 1. We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of **Span Divergent Limited** (the "Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").
- 2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular Issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable

4. The Statement includes the results of the following entities:

Parent Company:

i) Span Divergent Limited



Subsidiary:

- Dryfruit Factory LLP
- · Aranya Agri Biotech LLP
- Span Diagnostics LLP
- Biospan Scientific LLP
- Biospan Contamination Control Solutions Pvt Ltd
- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Y. B. Desai and Associates
Chartered Accountants

Firm Registration No. 102368W

esai & Ass

ered Accou

Mayank Y. Desai

Partner

Membership No. :- 108310

UDIN: 25108310 BM I 5NF8131

Date: - 13th August, 2025

Place :- Surat